US pharmaceutical companies are expected to announce strong unit growth in their drug sales for the second quarter of 1996, said a Reuters report.
The spotlight will be on some of the new products coming through, such as an agent for the treatment of obesity, Redux (dexfenfluramine), developed by Interneuron and co-marketed by the firm's marketing partner American Home Product's subsidiary Wyeth-Ayerst.
The drug group's earnings per share are expected to rise an average of 13% over 1995's second-quarter EPS, according to industry analysts' estimates complied by First Call. However, the US dollar's strength against the yen and the Deutschemark could trim sales growth measured in dollars by around 2%, said analysts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze